TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by MYDA Advisors LLC

MYDA Advisors LLC boosted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 37.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,000 shares of the biopharmaceutical company's stock after buying an additional 15,000 shares during the quarter. MYDA Advisors LLC's holdings in TG Therapeutics were worth $1,656,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Bleakley Financial Group LLC purchased a new position in shares of TG Therapeutics in the fourth quarter valued at approximately $245,000. Castellan Group purchased a new stake in shares of TG Therapeutics during the fourth quarter worth $8,539,000. Barclays PLC raised its position in shares of TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after buying an additional 158,323 shares during the last quarter. JPMorgan Chase & Co. boosted its position in TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after acquiring an additional 270,286 shares during the last quarter. Finally, Stratos Wealth Advisors LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at about $241,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

NASDAQ:TGTX opened at $38.32 on Friday. The company has a market capitalization of $6.02 billion, a P/E ratio of -383.16 and a beta of 2.14. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $43.32. The stock's fifty day moving average is $36.34 and its two-hundred day moving average is $31.92.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Equities analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TGTX. HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.